title: Use of omalizumab to improve desensitization safety in allergen immunotherapy.
authors.affiliation: Hospital Médica Sur, Colonia Toriello Guerra, Delegación Tlalpan, Mexico City, Mexico. Electronic address: Marlar1@prodigy.net.mx.
authors.forename: Désirée
authors.initials: D
authors.lastname: Larenas-Linnemann
authors.affiliation: Department for Pediatric Pneumology and Immunology, Charité University of Medicine, Berlin, Germany.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Wahn
authors.affiliation: Department of Pediatric Allergy and Pulmonology, University Luebeck, Airway Research-Center North (ARCN), Member of the "Deutsches Zentrums für Lungenforschung" (DZL), Lübeck, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Kopp
mesh_terms: D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001249:Asthma / Q000628:therapy*; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D000069444:Omalizumab
chemical_list: D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab